2026-06-15

Platinum volume spike — 4.0× the 20-day average (53 vs 13 avg)

CFTC BITCOIN speculator at extreme long — contrarian bear signal

CFTC SILVER speculator at extreme short — contrarian bull signal

OSINT: SpaceX Valuation Hits $2.5T, Becomes World’s 6th Largest Public Company

CFTC NATURAL GAS speculator at extreme long — contrarian bear signal

CFTC BITCOIN speculator at extreme long — contrarian bear signal

CFTC SILVER speculator at extreme short — contrarian bull signal

OSINT: Trump arrives in Geneva for G7 summit

CFTC NATURAL GAS speculator at extreme long — contrarian bear signal

CFTC BITCOIN speculator at extreme long — contrarian bear signal

CFTC SILVER speculator at extreme short — contrarian bull signal

CFTC NATURAL GAS speculator at extreme long — contrarian bear signal

OSINT: Israel Says Not Bound by Lebanon Clause, Tells Trump

CFTC BITCOIN speculator at extreme long — contrarian bear signal

CFTC SILVER speculator at extreme short — contrarian bull signal

CFTC NATURAL GAS speculator at extreme long — contrarian bear signal

OSINT: Iran claims military gains secured US MOU

Cotton bull 4.9% vs prior close ($72.94 → $76.50)

Cocoa bull 5.8% vs prior close ($3,779.00 → $3,998.00)

RBOB Gasoline bear 5.0% vs prior close ($3.05 → $2.90)

Heating Oil bear 5.5% vs prior close ($3.40 → $3.22)

WTI Crude Oil bear 4.5% vs prior close ($84.88 → $81.04)

OSINT: Belarus Declares No Military Action Against Ukraine

OSINT: S&P 500 jumps 1.7% on US‑Iran deal, adds $1.2 trn market cap

SOL open interest -63.3% — OI collapse

ETH open interest -67.8% — OI collapse

BTC open interest +235.9% — OI surge

ETH open interest -66.2% — OI collapse

SOL open interest +47.0% — OI surge

BTC open interest -49.0% — OI collapse

BTC open interest -40.7% — OI collapse

ETH open interest -65.8% — OI collapse

SOL open interest -64.3% — OI collapse

ETH open interest +221.9% — OI surge

SOL open interest +291.7% — OI surge

BTC open interest +216.4% — OI surge

SPYx/USDC has $39.7M volume but only $782K liquidity — thin market, slippage risk

SOL/USDC crashed -50.2% in 24h on orca DEX

ETH DEX volume/liquidity ratio elevated (0.58x) — strong on-chain trading activity

OSINT: Solana Firm Turns Down Forward's Bid Amid Treasury Pressure

SOL DEX volume/liquidity ratio elevated (1.01x) — strong on-chain trading activity

ETH DEX volume/liquidity ratio elevated (0.52x) — strong on-chain trading activity

Phase 3 trial terminated early — JOHNSON Treatment of Anemic Patients With Cancer Who Are Not Receiving Chemotherapy or R

Phase 3 trial terminated early — ELI A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabe

Phase 3 trial terminated early — ELI A Rheumatoid Arthritis Study in Participants on a Background Treatment of Methot

Phase 3 trial terminated early — ELI A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol

Phase 3 trial terminated early — BIOGEN A Study to Investigate the Radiological Onset of Action After Treatment Initiati

Phase 3 trial terminated early — BIOGEN Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmona

Phase 3 trial terminated early — BIOGEN Natalizumab and Chronic Inflammation

Phase 3 trial terminated early — BIOGEN Corticosteroids for Immune Reconstitution Inflammatory Syndrome (IRIS)

Phase 3 trial terminated early — BIOGEN Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and P

Phase 3 trial terminated early — AMGEN Multicenter,Single-arm Study to Evaluate Efficacy, Safety, & Pharmacokinetics of

Phase 3 trial terminated early — AMGEN A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinic

Phase 3 trial terminated early — AMGEN Effect of Darbepoetin Alfa (Aranesp®) on Anemia in Patients With Advanced Hormon

Phase 3 trial terminated early — AMGEN A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onse

Phase 3 trial terminated early — INCYTE A Study of Ruxolitinib in Pancreatic Cancer Patients

Phase 3 trial terminated early — INCYTE To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants W

Phase 3 trial terminated early — INCYTE To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participan

Phase 3 trial terminated early — Medtronic DIAM™ Spinal Stabilization System vs. Decompression, Formerly vs. Posterolateral

Phase 3 trial terminated early — Medtronic Diagnostic Outcome Trial in Heart Failure (DOT-HF Trial)

Phase 3 trial terminated early — Medtronic Condition of Approval Study

Phase 3 trial terminated early — AbbVie An Oral GnRH Antagonist to Treat Mild Autonomous Cortisol Excess (MACE) Due to A

Phase 3 trial terminated early — AbbVie Upadacitinib for Prurigo Nodularis

Phase 3 trial terminated early — ABBOTT Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular

Phase 3 trial terminated early — ABBOTT Comparative Study of the Effect of Ezetimibe Versus Extended-Release Niacin on A

Phase 3 trial terminated early — ABBOTT Effects of a Supplement Enriched in Hydroxymethylbutyrate and Vitamin D on Muscl

Phase 3 trial terminated early — ABBOTT Study to Examine the Longer-Term Efficacy and Safety of Sibutramine Hydrochlorid

Phase 3 trial terminated early — ABBOTT Catheter Ablation Versus Amiodarone for Shock Prophylaxis in Defibrillator Patie

Phase 3 trial terminated early — PFIZER Strategy for Adequate Blood Pressure Lowering in the Patients With Intracranial

Phase 3 trial terminated early — PFIZER Desvenlafaxine for Treatment of Hot Flashes in Women With Breast Cancer Taking T

Phase 3 trial terminated early — PFIZER Vaspect Study - An Open-Label Trial Of Donepezil in Vascular and Mixed Dementia

Phase 3 trial terminated early — GILEAD Study to Evaluate the Efficacy and Safety of Remdesivir in Participants With Sev

Phase 3 trial terminated early — GILEAD DORADO-EX: Long-Term Safety Extension Study to the Phase 3 DORADO Study (Protoco

Phase 3 trial terminated early — GILEAD Study of Cilofexor in Adults With Primary Sclerosing Cholangitis

Phase 3 trial terminated early — GILEAD Ambisome and Management of Culture-negative Neutropenic Fever Unresponsive to An

Phase 3 trial terminated early — GILEAD Rapid Start vs. Standard Start Antiretroviral Therapy (ART) in HIV

Phase 3 trial terminated early — GILEAD Value of Inhaled Treatment With Aztreonam Lysine in Bronchiectasis

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

5 congress members traded TSCO — net BEAR (0B/0S)

OSINT: Solana Firm Turns Down Forward's Bid Amid Treasury Pressure

OSINT: US Air Force B‑52 bomber crashes at Edwards AFB, crew status unknown

5 congress members traded TSCO — net BEAR (0B/0S)

Q2-2025: Beat consensus by 6.5% — EPS $3.61 vs $3.3908 estimate

Q1-2026: Beat consensus by 9.6% — EPS $4.75 vs $4.3336 estimate

Q3-2025: Missed consensus by 14.2% — EPS $-1.22 vs $-1.0686 estimate

Q4-2025: Missed consensus by 333.0% — EPS $-4.54 vs $-1.0486 estimate

Missed consensus by 16.7% — EPS $-1.25 vs $-1.071 estimate

Q1-2026: Beat consensus by 9.7% — EPS $-1.46 vs $-1.6177 estimate

Beat consensus by 11.0% — EPS $2.09 vs $1.883 estimate

Q1-2026: Missed consensus by 8.4% — EPS $0.8 vs $0.8736 estimate

Q4-2025: Beat consensus by 10.2% — EPS $0.4 vs $0.3629 estimate

Q1-2026: Beat consensus by 7.6% — EPS $1.5 vs $1.3943 estimate

Q3-2025: Beat consensus by 5.2% — EPS $1.58 vs $1.5012 estimate

Q1-2026: Beat consensus by 207.8% — EPS $0.011 vs $-0.0102 estimate

Q4-2026: Missed consensus by 198.0% — EPS $-0.01 vs $0.0102 estimate

Q1-2026: Missed consensus by 595.8% — EPS $-0.78 vs $-0.1121 estimate

Q4-2025: Missed consensus by 25.8% — EPS $-0.29 vs $-0.2305 estimate

Q1-2020: Missed consensus by 88.1% — EPS $0.2 vs $1.6766 estimate

Q4-2019: Beat consensus by 241.0% — EPS $4.34 vs $1.2726 estimate

Q3-2024: Beat consensus by 201.9% — EPS $3552.91 vs $1176.8008 estimate

Q4-2024: Missed consensus by 296.3% — EPS $-791.835 vs $403.2991 estimate

Q1-2026: Beat consensus by 12.0% — EPS $0.38 vs $0.3392 estimate

Beat consensus by 7.9% — EPS $0.26 vs $0.241 estimate

Q4-2025: Beat consensus by 5.8% — EPS $0.31 vs $0.2929 estimate

Q3-2025: Beat consensus by 10.9% — EPS $0.43 vs $0.3876 estimate

Q2-2025: Missed consensus by 25.7% — EPS $0.25 vs $0.3366 estimate

Q1-2026: Beat consensus by 24.6% — EPS $1.15 vs $0.9229 estimate

Q3-2025: Missed consensus by 9.6% — EPS $0.93 vs $1.0288 estimate

Q2-2025: Beat consensus by 10.4% — EPS $1.302 vs $1.1797 estimate

Missed consensus by 23.7% — EPS $13.2 vs $17.304 estimate

Beat consensus by 253.0% — EPS $16 vs $4.532 estimate

Missed consensus by 51.0% — EPS $0.1 vs $0.204 estimate

Missed consensus by 30.7% — EPS $-0.4 vs $-0.306 estimate

Missed consensus by 197.6% — EPS $-168.35 vs $-56.56 estimate

Missed consensus by 61.5% — EPS $-21.7 vs $-13.433 estimate

Q1-2024: Missed consensus by 47.1% — EPS $-18.2 vs $-12.3725 estimate

Q1-2027: Beat consensus by 5.6% — EPS $0.14 vs $0.1326 estimate

Beat consensus by 18.1% — EPS $0.66 vs $0.559 estimate

Q1-2026: Beat consensus by 43.1% — EPS $0.26 vs $0.1817 estimate

Q3-2025: Beat consensus by 15.8% — EPS $0.61 vs $0.5266 estimate

Q4-2025: Missed consensus by 7.5% — EPS $0.61 vs $0.6592 estimate

Q2-2025: Beat consensus by 13.7% — EPS $0.67 vs $0.5893 estimate

Q1-2026: Beat consensus by 11.7% — EPS $0.3 vs $0.2686 estimate

Beat consensus by 586.3% — EPS $140 vs $20.4 estimate

Missed consensus by 14.2% — EPS $140 vs $163.2 estimate

Q1-2012: Missed consensus by 134.2% — EPS $-180 vs $-76.8468 estimate

Q2-2012: Beat consensus by 126.3% — EPS $20 vs $-76.1532 estimate

Q4-2025: Missed consensus by 138.1% — EPS $-0.17 vs $-0.0714 estimate

Missed consensus by 56.9% — EPS $-0.08 vs $-0.051 estimate

Q1-2026: Beat consensus by 34.6% — EPS $-0.04 vs $-0.0612 estimate

Q3-2025: Missed consensus by 929.4% — EPS $-0.21 vs $-0.0204 estimate

Q2-2025: Missed consensus by 7.6% — EPS $0.91 vs $0.9847 estimate

Q1-2026: Beat consensus by 9.5% — EPS $1.64 vs $1.4975 estimate

Q2-2025: Missed consensus by 14.4% — EPS $23.14 vs $27.0246 estimate

Q1-2026: Beat consensus by 66.0% — EPS $42.52 vs $25.6166 estimate

Q3-2025: Missed consensus by 161.9% — EPS $-9.96 vs $16.1024 estimate

Missed consensus by 354.1% — EPS $-28.11406 vs $11.062 estimate

Q4-2025: Beat consensus by 42.0% — EPS $0.25 vs $0.1761 estimate

Q1-2026: Beat consensus by 5.2% — EPS $0.22 vs $0.2091 estimate

Q4-2025: Beat consensus by 76.9% — EPS $0.15 vs $0.0848 estimate

Q1-2026: Missed consensus by 11.4% — EPS $0.11 vs $0.1241 estimate

Q3-2025: Beat consensus by 15.5% — EPS $0.14 vs $0.1212 estimate

Beat consensus by 98.4% — EPS $1.72 vs $0.867 estimate

Q2-2025: Beat consensus by 108.2% — EPS $1.55 vs $0.7446 estimate

Q4-2025: Missed consensus by 31.7% — EPS $0.61 vs $0.8925 estimate

Q1-2026: Missed consensus by 56.5% — EPS $0.44 vs $1.0124 estimate

Q1-2026: Beat consensus by 158.6% — EPS $0.12 vs $0.0464 estimate

Q2-2025: Missed consensus by 35.6% — EPS $0.03 vs $0.0466 estimate

Q3-2025: Missed consensus by 38.9% — EPS $0.03 vs $0.0491 estimate

Q4-2025: Beat consensus by 240.3% — EPS $0.18 vs $0.0529 estimate

Q2-2026: Missed consensus by 11.2% — EPS $-0.54 vs $-0.4855 estimate

Q3-2026: Beat consensus by 9.2% — EPS $-0.45 vs $-0.4957 estimate

Q4-2025: Beat consensus by 14.7% — EPS $-0.432 vs $-0.5066 estimate

Q1-2026: Missed consensus by 27.2% — EPS $0.023 vs $0.0316 estimate

Q2-2025: Missed consensus by 37.3% — EPS $0.016 vs $0.0255 estimate

Q4-2025: Beat consensus by 5.3% — EPS $0.054 vs $0.0513 estimate

Q3-2025: Beat consensus by 18.9% — EPS $0.034 vs $0.0286 estimate

Missed consensus by 9.5% — EPS $-38.19 vs $-34.884 estimate

Missed consensus by 71.6% — EPS $-6.65 vs $-3.876 estimate

Q1-2024: Beat consensus by 15.2% — EPS $-68.4 vs $-80.6208 estimate

Q2-2024: Missed consensus by 107.6% — EPS $-105.83 vs $-50.9694 estimate

Missed consensus by 48.3% — EPS $0.03 vs $0.058 estimate

Q2-2026: Beat consensus by 89.3% — EPS $0.16 vs $0.0845 estimate

Q1-2026: Beat consensus by 52.2% — EPS $0.098 vs $0.0644 estimate

Q4-2025: Beat consensus by 9.8% — EPS $-0.5 vs $-0.5542 estimate

Q3-2025: Missed consensus by 108.2% — EPS $-1.35 vs $-0.6484 estimate

Q2-2025: Beat consensus by 48.4% — EPS $-0.39 vs $-0.7561 estimate

Q3-2025: Missed consensus by 17.6% — EPS $1.75 vs $2.1248 estimate

Q4-2025: Missed consensus by 77.2% — EPS $0.54 vs $2.3689 estimate

Q2-2025: Missed consensus by 42.5% — EPS $0.71 vs $1.2342 estimate

Q1-2026: Beat consensus by 112.2% — EPS $2.87 vs $1.3526 estimate

Q1-2026: Beat consensus by 12.0% — EPS $0.15 vs $0.1339 estimate

Q1-2026: Beat consensus by 9.5% — EPS $1.99 vs $1.8176 estimate

Q4-2025: Beat consensus by 26.4% — EPS $1.242 vs $0.9826 estimate

Q4-2025: Missed consensus by 50.5% — EPS $0.01 vs $0.0202 estimate

OSINT: Belarus Declares No Military Action Against Ukraine

OSINT: Belarus Declares No Military Action Against Ukraine

OSINT: S&P 500 jumps 1.7% on US‑Iran deal, adds $1.2 trn market cap

OSINT: US Air Force B‑52 bomber crashes at Edwards AFB, crew status unknown

OSINT: S&P 500 jumps 1.7% on US‑Iran deal, adds $1.2 trn market cap

OSINT: Belarus Declares No Military Action Against Ukraine